- Home
- VCRE vs PPHC Comparison
VCRE vs PPHC Comparison
Compare VCRE & PPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | VCRE | PPHC |
|---|---|---|
| Founded | N/A | N/A |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.4M | 305.8M |
| IPO Year | 2026 | 2025 |
Fundamental Metrics
Financial Performance| Metric | VCRE | PPHC |
|---|---|---|
| Price | $9.80 | $11.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.0K | ★ 139.6K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $186,541,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.72 |
| 52 Week Low | $10.03 | $7.01 |
| 52 Week High | $13.15 | $15.15 |
Technical Indicators
Market Signals| Indicator | VCRE | PPHC |
|---|---|---|
| Relative Strength Index (RSI) | 35.72 | 54.72 |
| Support Level | N/A | $11.34 |
| Resistance Level | $13.00 | $12.85 |
| Average True Range (ATR) | 0.55 | 0.80 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 9.43 | 48.45 |
Price Performance
Historical ComparisonAbout VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
About PPHC Public Policy Holding Company Inc. Common Stock
Public Policy Holding Co Inc operates as a advisory firm. The company also operates a portfolio of independent firms that offer public affairs, crisis management, lobbying, and advocacy services on behalf of the corporate, trade association, and non-profit client organisations. Its business comprises of three reporting segments - Government Relations Consulting, Corporate Communications & Public Affairs Consulting and Compliance and Insights Services.